K. R. Sprouse

This study shows that hybrid immunity and vaccine boosters provide potent neutralizing activity against Omicron BA.1 and BA.2, while breakthrough infections induce nasal mucosal neutralization and identify an ultrapotent pan-variant antibody.

This study evaluates neutralizing activity against Omicron BA.1 and BA.2 variants elicited by various vaccines and finds that booster doses enhance neutralizing titers and breadth across all vaccine platforms.

This study compares neutralizing antibody responses to SARS-CoV-2 variants in vaccinated humans and mice, finding that mice do not accurately reflect the breadth and potency seen in humans.

This study investigates how delta and kappa SARS-CoV-2 variants evade immune responses by altering antigenic sites and reducing ACE2 binding affinity.

This study shows that vaccines encoding a prefusion-stabilized SARS-CoV-2 spike protein induce higher neutralizing antibody titers and better variant cross-neutralization compared to other vaccines or infection.

This study shows that Omicron variant's spike protein has enhanced ACE2 binding and reduces neutralizing activity, but some broadly neutralizing antibodies remain effective.

The paper examines antibody responses in Delta breakthrough infections, finding they are more potent, durable, and broad compared to vaccinated-only or infected-only individuals.